The School of Medicine of the Medical Sciences Campus of the University of Puerto Rico (UPR) has announced its collaboration with RECOVER-VITAL in a pioneering initiative to explore treatments against persistent COVID, also known as Long COVID or PASC (Post Acute Sequelae of SARS CoV-2 infection).
Led by Dr. Jorge Santana Bagur, the ACTU Project is recruiting volunteers to participate in this important study, which aims to investigate whether PAXLOVID, an antiviral medication combining nirmatrelvir and ritonavir and previously successful in treating mild to moderate COVID-19 infections, may be effective in treating prolonged COVID symptoms.
Dr. Santana Bagur expressed the urgency of understanding and finding effective treatments for this condition that continues to impact the quality of life of many individuals. He emphasized that this study is a critical step in the search for answers and best practices to support patients in the long term.
RECOVER-VITAL is part of a broader effort called RECOVER, funded by the National Institutes of Health and coordinated by the prestigious Duke Clinical Research Institute (DCRI) with collaboration from renowned doctors Kanecia Zimmerman, Richard Whitley, and Lindsey Baden.
Participants in the clinical trial will take the study intervention for up to 25 days, with detailed follow-up to evaluate the effectiveness of the treatment. PAXLOVID, provided by Pfizer, Inc., will be used to assess whether a prolonged course of treatment can offer sustained relief to patients.
For those interested in more information or participating in the study, they can contact the ACTU Project at 787-767-9192 or 787-685-5290. Additional details about the study can also be found on trials.recovercovid.org/vital.
The commitment of the School of Medicine of the UPR Medical Sciences Campus to cutting-edge medical research and the well-being of the Puerto Rican community is demonstrated through their dedication to improving public health and contributing to global medical knowledge.